DKK1 and neoplasm: In vivo studies indicated that these anti-DKK1 antibody leads targeting DKK1 CDR1 are potent in inhibition of tumor growth and may have promising efficacy as cancer immunotherapy due to activation of the Wnt non-canonical pathway.